Pathologic and Therapeutic Schwann Cells
Shurin MR., Wheeler SE., Zhong H., Zhou Y.
Narrative Review on Neuroinflammation, Autoimmune Research, published in Cells (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Cells (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40940747
- PMCID
- PMC12428265
- DOI
- 10.3390/cells14171336
- Citations
- 7
Abstract (original English)
Schwann cells (SCs) are the primary glial cells of the Peripheral Nervous System (PNS), which insulate and provide protection and nutrients to the axons. Technological and experimental advances in neuroscience, focusing on the biology of SCs, their interactions with other cells, and their role in the pathogenesis of various diseases, have paved the way for exploring new treatment strategies that aim to harness the direct protective or causative properties of SCs in neurological disorders. SCs express cytokines, chemokines, neurotrophic growth factors, matrix metalloproteinases, extracellular matrix proteins, and extracellular vesicles, which promote the inherent potential of the injured neurons to survive and accelerate axonal elongation. The ability of SCs to support the development and functioning of neurons is lost in certain hereditary, autoimmune, metabolic, traumatic, and toxic conditions, suggesting their role in specific neurological diseases. Thus, targeting, modifying, and replacing SC strategies, as well as utilizing SC-derived factors and exosomes, have been considered novel therapeutic opportunities for neuropathological conditions. Preclinical and clinical data have demonstrated that SCs and SC-derived factors can serve as viable cell therapy for reconstructing the local tissue microenvironment and promoting nerve anatomical and functional recovery in both periphe
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies.
Systematic Review on Neuroinflammation, published in Tissue Eng Regen Med (2026) — summary generated from the PubMed abstract.
- 2026
Tissue Eng Regen Med - Level ASystematic ReviewPubMed
The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.
Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 8
Neurosurg Rev - Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level ASystematic ReviewEurope PMC
Efficacy of Exosome-Based Therapies for Skin Rejuvenation: A Systematic Review of Human Studies
Systematic Review on Neuroinflammation, Skin Aging, published in Cureus (2026) — summary generated from the PubMed abstract.
- 2026
Cureus - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level ASystematic ReviewEurope PMC
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Multiple System Atrophy: Systematic Review
Systematic Review with a reported sample of 123 on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in Biologics (2026) — summary generated from the PubMed abstract.
- 2026
- n = 123
Biologics